RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that its abstract submission to the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting has been accepted. The meeting will be held February 4–8, 2026 in Savannah, Georgia. Researchers including Christophe ...